17-Jul-2026
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
Globe Newswire (Mon, 8-Jun 9:01 AM ET)
The Multi-Billion-Dollar Search for Better Glioblastoma Treatments
Globe Newswire (Wed, 3-Jun 9:28 AM ET)
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
Business Wire (Mon, 1-Jun 1:52 PM ET)
Globe Newswire (Tue, 26-May 4:00 PM ET)
Business Wire (Tue, 26-May 1:27 PM ET)
Portnoy Law Firm Announces Class Action on Behalf of ImmunityBio, Inc. Investors
Globe Newswire (Tue, 26-May 9:05 AM ET)
PRNewswire (Tue, 26-May 9:01 AM ET)
Business Wire (Tue, 26-May 8:56 AM ET)
PRNewswire (Tue, 26-May 4:52 AM ET)
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Immunitybio trades on the NASDAQ stock market under the symbol IBRX.
As of July 17, 2026, IBRX stock price climbed to $7.68 with 7,882,987 million shares trading.
IBRX has a beta of 1.85, meaning it tends to be more sensitive to market movements. IBRX has a correlation of 0.04 to the broad based SPY ETF.
IBRX has a market cap of $8.04 billion. This is considered a Mid Cap stock.
Last quarter Immunitybio reported $44 million in Revenue and -$.08 earnings per share. This beat revenue expectation by $837,000 and missed earnings estimates by -$.01.
In the last 3 years, IBRX traded as high as $12.43 and as low as $1.25.
The top ETF exchange traded funds that IBRX belongs to (by Net Assets): VTI, XBI, IWM, VB, VBK.
IBRX has outperformed the market in the last year with a return of +171.4%, while the SPY ETF gained +19.5%. However, in the most recent history, IBRX shares have underperformed the stock market with its stock returning -0.3% in the last 3 month period and -18.6% for the last 2 week period, while SPY has returned +4.9% and -0.2%, respectively.
IBRX support price is $7.09 and resistance is $7.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IBRX shares will trade within this expected range on the day.
